A randomized double-blind placebo-controlled trial to assess the effects of 17 beta-oestradiol 1mg + drospirenone 2mg administration on cognitive function in early postmenopausal women.
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Estradiol/drospirenone (Primary)
- Indications Menopausal syndrome
- Focus Therapeutic Use
- 30 Jan 2014 Status changed to completed as per Australian New Zealand Clinical Trials Registry record.
- 15 May 2009 New trial record